Form 4: Omega Therapeutics Director Richard N. Kender Acquires Stock Options
SEC Filing Form 4
Director Richard N. Kender acquired stock options for 50,000 shares of Omega Therapeutics, Inc. on June 20, 2024.
Summary
- Richard N. Kender, a director of Omega Therapeutics, Inc., filed a Form 4 to report changes in beneficial ownership.
- On June 20, 2024, Kender acquired stock options for 50,000 shares of Omega Therapeutics common stock at an exercise price of $2.20.
- The options vest in 36 equal monthly installments, becoming fully vested on the third anniversary of the grant date, contingent upon continued service on the Board of Directors.
- Following the transaction, Kender directly owns derivative securities consisting of 50,000 stock options.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, which is neutral in sentiment.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of stock option grant and transaction. |
| 06/21/2024 | Date of Form 4 filing. |
| 06/19/2034 | Expiration date of the stock options. |
Keywords
Form 4, Omega Therapeutics, Stock Options, Beneficial Ownership, Director, Kender, OMGA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.